Harrow’s (HROW) Buy Rating Reaffirmed at BTIG Research

Harrow (NASDAQ:HROW)‘s stock had its “buy” rating reissued by equities research analysts at BTIG Research in a report issued on Wednesday, Benzinga reports. They presently have a $63.00 price objective on the stock. BTIG Research‘s price objective suggests a potential upside of 107.51% from the stock’s previous close.

A number of other research analysts have also commented on HROW. Wall Street Zen upgraded shares of Harrow from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Zacks Research downgraded Harrow from a “hold” rating to a “strong sell” rating in a research report on Tuesday, November 3rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Harrow in a research note on Friday, October 16th. Finally, Leerink Partners assumed coverage on Harrow in a research report on Wednesday, September 9th. They set an “outperform” rating and a $45.00 target price for the company. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $66.17.

Harrow Stock Up 10.5%

HROW stock opened at $30.36 on Wednesday. The firm has a 50 day moving average of $31.30 and a 200-day moving average of $37.74. Harrow has a 12 month low of $25.76 and a 12 month high of $54.85. The company has a debt-to-equity ratio of 19.70, a quick ratio of 2.08 and a current ratio of 2.24.

Harrow (NASDAQ:HROW) last posted its earnings results on Monday, November 9th. The company reported $0.25 earnings per share for the quarter, topping analysts’ consensus estimates of $0.19 by $0.06. Harrow had a negative net margin of 9.39% and a negative return on equity of 68.20%. The business had revenue of $99.30 million for the quarter, compared to analyst estimates of $98.59 million. Equities analysts expect that Harrow will post -0.02 EPS for the current fiscal year.

Insiders Place Their Bets

In other Harrow news, insider Amir Shojaei sold 11,250 shares of Harrow stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $40.00, for a total transaction of $450,000.00. Following the completion of the sale, the insider directly owned 11,250 shares in the company, valued at $450,000. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 12.80% of the stock is owned by corporate insiders.

Institutional Trading of Harrow

Several institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. purchased a new position in Harrow in the second quarter worth $116,373,000. Bamco Inc. NY purchased a new stake in Harrow during the second quarter valued at about $34,373,000. Jupiter Topco LLC purchased a new stake in Harrow during the second quarter valued at about $24,596,000. Rice Hall James & Associates LLC bought a new stake in Harrow during the second quarter worth about $16,459,000. Finally, Dimensional Fund Advisors LP lifted its stake in Harrow by 56.4% during the first quarter. Dimensional Fund Advisors LP now owns 579,520 shares of the company’s stock worth $20,428,000 after purchasing an additional 208,972 shares during the last quarter. Hedge funds and other institutional investors own 72.76% of the company’s stock.

Key Harrow News

Here are the key news stories impacting Harrow this week:

• Positive Sentiment: Third-quarter revenue reached a record $99.3 million, up 39% year over year. Branded revenue rose 62% to $83.5 million, demonstrating strong growth in Harrow’s core products. Harrow third-quarter results
• Positive Sentiment: Harrow forecast fourth-quarter revenue of approximately $136 million to $151 million and reaffirmed 2026 revenue guidance of $350 million to $365 million, modestly above the roughly $349.7 million consensus estimate. Harrow revenue and EBITDA outlook
• Neutral Sentiment: Harrow reported $9.8 million in GAAP net income, versus a $17.3 million loss in the prior quarter. The result included a $5 million litigation-settlement gain, so it may not reflect recurring operating performance. Harrow third-quarter results
• Negative Sentiment: The company lowered its full-year 2026 adjusted EBITDA outlook to more than $40 million, from its prior range of $80 million to $100 million. Third-quarter adjusted EBITDA was $21.2 million, below $22.8 million a year earlier. The sharp outlook reduction could temper enthusiasm for the strong revenue growth. Harrow earnings guidance

Harrow Company Profile

Harrow is a pharmaceutical company focused on developing, acquiring and commercializing treatments for eye conditions. Its portfolio includes prescription ophthalmic medicines used in areas such as dry eye disease, eye inflammation and pain management, as well as products used in eye surgery and clinical settings. The company markets branded products including VEVYE, a treatment for dry eye disease, and IHEEZO, an ophthalmic anesthetic gel. Through its ImprimisRx subsidiary, Harrow also provides compounded medications and related services for ophthalmology practices and patients.